CTLA4 and melanoma: Pertinent to this concept, a recent report of melanoma patients treated with combination CTLA-4 and PD-1 blockade associated their risk of developing immune-related adverse events with the expansion of CD21lo B cells with a nonlymphoid tissue–homing profile (72).